Differential immunohistochemical staining for DNA topoisomerase II α and β in human tissues and for DNA topoisomerase II β in non-Hodgkin's lymphomas

Modern Pathology

Volumn 10, Issue 3, 1997, Pages 168-175

  Bauman, Mark E ^a   Holden, Joseph A ^a   Brown, Karen A ^a   Harker, W Graydon ^a   Perkins, Sherrie L ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

DNA topoisomerae II; Human malignancies; Immunohistochemical staining; Non Hodgkin's lymphoma; Non neoplastic human tissues

Indexed keywords

DNA TOPOISOMERASE; DOXORUBICIN; ETOPOSIDE;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

ANTIGENS, NEOPLASM; BLOTTING, WESTERN; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; LYMPHOMA, NON-HODGKIN;

EID: 0030939518     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Uemura T, Ohjura H, Adachi Y, Morino K, Shiozaki K, Yanagida M. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell 1987;50:917-25.
2. Schneider E, Yaw-Huei H, Liu LF. DNA topoisomerases as anticancer drug targets. Adv Pharmacol 1990;21:149-83.
3. Liu LF. DNA topoisomerase poisons as antitumor drugs. Ann Rev Biochem 1989;58:351-75.
4. Sinha BK. Topoisomerase inhibitors: a review of their therapeutic potential in cancer. Drugs 1995;49:11-9.
5. Robinson MJ, Osheroff M. Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II. Biochemistry 1991;30:1807-13.
6. Zhang H, D'Arpa PD, Liu LF. A model for tumor cell killing by topoisomerase poisons. Cancer Cells 1990;2:23-7.
7. Holden JA, Perkins SL, Snow GW, Kjeldsberg CR. Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas. Am J Clin Path 1995;104:54-9.
8. Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA, et al. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 1994;83: 517-30.
9. Davies SM, Robson CN, Davies SL, Hickson ID. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem 1988;263:17724-9.
10. Klumper E, Giaccone G, Pieters R, Broekema G, van Ark-Otte J, van Wering ER, et al. Topoisomerase IIa gene expression in childhood acute lymphoblastic leukemia. Leukemia 1995;9: 1653-60.
11. Tan KB, Dorman TE, Falls KM, Chung TD, Mirabelli CK, Crooke ST, et al. Topoisomerase IIa and topoisomerase IIb genes: characterization and mapping to human chromosomes 17 and 3, respectively. Can Res 1992;52:231-4.
12. Chung TDY, Drake FH, Tan KB, Per SR, Crooke ST, Mirabelli CK. Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isoenzymes. Proc Natl Acad Sci U S A 1989;86:9431-5.
13. Holden JA, Rolfson DH, Wittwer CT. The distribution of immunoreactive topoisomerase II protein in human tissues and neoplasms. Oncol Res 1992;4:157-66.
14. Kim R, Hirabayashi N, Nishiyama M, Saeki S, Toge T, Okada K. Expression of MFR1 GST-p, and topoisomerase II as an indicator of clinical response to adriamycin. Anticancer Res 1991;11:429-32.
15. Holden JA, Rolfson DH, Wittwer CT. Human DXA topoisomerase II: evaluation of enzyme activity in normal and neoplastic tissues. Biochemistry 1990;29:2127-34.
16. D'Andrea MRD, Farber PA, Foglesong PD. Immunohistochemical detection of DNA topoisomerases IIa and IIb compared with detection of Ki-67, a marker of cellular proliferation, in human tumors. Appl Immunohistochem 1994;2: 177-85.
17. Ellis AL, Nowak B, Plunkett W, Zwelling LA. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent. Can Chem Pharm 1994;34:249-56.
18. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 1989;28:8154-60.
19. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180- kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 1991; 2:209-14.
20. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, et al. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 1991;51:6592-5.
21. Holden JA, Snow GW, Perkins SL, Jolles CJ, Kjeldsberg CR. Immunohistochemical staining for DNA topoisomerase II in frozen and formalin-fixed, paraffin-embedded, human tissues. Mod Path 1994;7:829-34.
22. Tsai-Pflugfelder M, Liu LF, Liu AA, Tewey KM, Whang-Peng J, Knutsen T, et al. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22, Proc Natl Acad Sci U SA 1988;85:7177-81.
23. Harker WG, Slade DL, Drake FH, Parr RL. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase IIb isoform. Biochemistry 1991;30:9953-61.
24. Harker WG, Slade DL, Parr RL, Feldhoff PW, Sullivan DM, Holguin MH. Alterations in the topoisomerase IIa gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase IIb enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res 1995;55:1707-16.
25. Juenke JM, Holden JA. The distribution of DNA topoisomerase II isoforms in differentiated adult mouse tissues. Biochim Biophys Acta 1993;1216:191-6.
26. Capranico G, Tinelli S, Austin CA, Fisher ML, Zunino F. Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta 1992;1132:43-8.
27. Park SH, Yoon JH, Cho HA, Kwon YD, Seong RH, Hong SH, et al. Isolation and characterization of the promoter region of the rat DNA topoisomerase II α gene. J Biochem 1995;118: 725-33.
28. Heck MM, Hittelman WN, Earnshaw WC. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci U S A 1988;85:1086-90.
29. Heck MS, Earnshaw WC. Topoisomerase II: a specific marker for cell proliferation. J Cell Biol 1986;103:2569-81.
30. Giaccone G, van Ark-Otte J, Scagliotti G, Capranico G, van der Valk P, Rubio G, et al. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. Biochim Biophys Acta 1995;1264:337-46.
31. Houlbrook S, Addison CM, Davies SL, Carmichael J, Stratford IJ, Harris AL, et al. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer 1995;2:1454-61.
32. Petrov P, Drake FH, Loranger A, Huang W, Hancock R. Localization of DNA topoisomerase II in Chinese hamster fibroblasts by confocal and electron microscopy. Exp Cell Res 1993;204:73-81.
33. Zini N, Martelli AM, Sabatelli P, Santi S, Necri C, Astaldi-Ricotti GC, et al. The 180-kDa isoform of topoisomerase II is localized in the nucleolus and belongs to the structural elements of the nucleolar remnant. Exp Cell Res 1992;200: 460-6.